Ansa Biotechnologies, a synthetic DNA maker based in Emeryville, California, said on 18 November 2026 that it had closed a $71.5m Series C round led by Blue Water Life Science Advisors. The company said the round was oversubscribed.
Four new investors joined: Illumina Ventures, BEVC, Lightscape Partners and Agent Capital. Existing backers Cerberus Ventures, Fall Line Capital, Dauntless Ventures and Altitude Life Science Ventures also invested. The round brought Ansa's total funding to $211m. The company did not disclose a valuation, revenue or headcount.
The raise came just over a year after a $54.4m Series B led by Cerberus Ventures, which Ansa announced in October 2025.
“Our growth reflects the demand unlocked when scientists can reliably obtain sequences that previously held their projects back. This oversubscribed financing validates our commercial success and gives us the resources to expand our capacity, serve more customers, and drive the next generation of biological innovation.”Jason T. Gammack, CEO, Ansa Biotechnologies
What Ansa does
Ansa builds DNA with enzymes rather than the chemical process that has long been standard in the industry. The company said conventional methods struggle with long or complex sequences and can be unreliable to manufacture, which can stop researchers from turning computer-designed sequences into physical DNA they can test.
It sells two kinds of product: clonal DNA of up to 50 kilobases that it describes as sequence-perfect, and double-stranded linear DNA fragments that are checked by sequencing. Every order goes through biosecurity screening. Under its On-Time Guarantee, a customer whose order does not ship by the promised date pays nothing for it. Ansa launched the guarantee shortly before its Series B.
The company said it had quadrupled its manufacturing capacity over the past year. Its customers work in drug discovery, cell and gene therapy, vaccines and agrigenomics, among other fields. Ansa linked rising demand to AI-driven drug discovery and biological design, which call for longer and more complex sequences that can be made and tested to check and improve the models.
Who invested
Blue Water Life Science Advisors already backed Ansa and took part in its Series B. Its founder and chief investment officer, Nate Cornell, joined the board with this round. In the release he said the firm had supported the company's plans from the start and that the money would help it add capabilities and grow operations to meet demand.
Nick Naclerio, a founding partner of Illumina Ventures and a former senior vice-president at Illumina, also joined the board. He said the value of AI-designed biology depends on being able to build and test what models propose, and that Ansa's mix of hard-to-make DNA and a delivery date customers can plan around was why the firm invested. Ion Genomics carried the same comments in its report on the round.
Brad Crutchfield, a former chief commercial officer of 10x Genomics and former head of Bio-Rad Laboratories' Life Science Group, joined as an independent director. Rowan Chapman, a co-founder of BEVC, became a board observer. Matthew McManus is leaving the board after three years, chief executive Jason T. Gammack said.
What the money is for
Ansa did not give a detailed breakdown. Gammack said the funds would be used to add capacity, take on more customers and support the next wave of biological research. Ion Genomics reported that the new funds would go towards more capacity and more customers.
The company has raised money steadily as it has moved from development into sales. Its Series B, of which $45.2m had closed with a further $9.2m committed at the time of the announcement, was meant to expand US manufacturing and improve customer service. Fall Line Capital, AIM13 and Black Opal Ventures were new investors in that round. VC News Daily also reported the Series C, with the same amount, lead investor and total.
Company website: ansabio.com
